(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Interim Analysis of Phase III Clinical Trial of Izalontamab Brengitecan (BL-B01D1/iza-bren) for Locally Advanced, Recurrent or Metastatic HR+HER2- Breast Cancer Achieving Primary Endpoint